SBIR/STTR Research Award

A Highly Parallel and Sensitive Assay System for Chemical Genomics

Award identifier 141c9fecc32fc7fbb60002f97943ebbede1bde49130be9612aa233a674487727Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$199,880

Program and phase

SBIR · Phase I

Award year

2005

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
PROGNOSYS BIOSCIENCES, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2005-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): We propose to commercialize a proven, highly-parallel technology for chemical genomics in yeast. The technology is called Haplolnsufficiency Profiling, or HIP. Heterozygous deletion strains of Saccharomyces cerevisiae grow more slowly in the presence of a compound that specifically inhibits the gene product of the heterozygous locus. A set of approximately 6,000 strains representing deletions in all the genes in the yeast genome are grown together in a pool, and their relative growth rates are an indicator of relative fitness in the presence or absence of drug. Each deletion strain is tagged with a different oligonucleotide sequence, so that the responses of all approximately 6,000 strains can be read out simultaneously on a single microarray. As a result, the HIP assay can be used to interrogate the mechanism of action of medically relevant compounds in a comprehensive and unbiased fashion. In the Phase I proposal we focus on improvements to the readout portion of the assay. The completion of the aims will lay the foundation for building a complete, highperformance high-throughput small molecule profiling instrument suite. This powerful and cost-effective chemical genomics technology has the potential to play a significant role in drug development and basic research. Traditional approaches to drug development are inefficient, and there is a pressing human health need for new information-rich technologies that can greatly improve the process of identifying and validating targets and developing drugs.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.